The typical respiratory syncytial virus (RSV) season is from November to March. To prevent RSV in infants, Sanofi’s Beyfortus and Merck’s Enflonsia* can be administered. For adults, Pfizer’s Abrysvo and Moderna’s mResvia can be administered to prevent RSV. Additionally, Abrysvo has been approved by the CDC to be given to pregnant women during the RSV season who are 32 to 36 weeks gestation.
PCA is contracted with Sanofi, Merck, Pfizer, and Moderna, providing our members with the flexibility to choose the vaccine(s) that best meet their patients’ needs. See below for the billing and coding guides for these vaccines, as well as other relevant resources.
